RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer

Background: Circulating tumor cells (CTCs) hold huge potential for both clinical applications and basic research into the management of cancer, but the relationship between CTC count and cervical cancer prognosis remains unclear. Therefore, research on this topic is urgently required. Objective: This study investigated whether CTCs were detectable in patients with cervical cancer and whether CTC count was an indicator of prognosis. Methods: We enrolled 107 patients with pathologically confirmed cervical cancer. CTCs were detected after radiotherapy or concurrent cisplatin-containing chemotherapy in all patients. We evaluated all medical records and imaging data as well as follow-up information to calculate progression-free survival (PFS). PFS was defined as the time until first diagnosis of tumor progression or death. We also analyzed the relationship between CTC count and patient age, disease stage, histological differentiation, tumor size, and pathological type. Results: CTCs were identified in 86 of 107 patients (80%), and the CTC count ranged from 0 to 27 cells in 3.2 mL blood. The median progression-free survival (PFS) was 43.1 months. Patients in which CTCs were detected had a significantly shorter PFS than CTC-negative patients (P = 0.018). Multivariate analysis indicated that CTC count was an independent negative prognostic factor for survival. However, no correlation was observed between CTC count and patient age, disease stage, histological differentiation, tumor size, and pathological type. Conclusion: CTC count is an independent negative prognostic factor for cervical cancer.

Download Full-text

EMMPRIN Is an Independent Negative Prognostic Factor for Patients with Astrocytic Glioma

PLoS ONE ◽

10.1371/journal.pone.0058069 ◽

2013 ◽

Vol 8 (3) ◽

pp. e58069 ◽

Cited By ~ 20

Author(s):

Li Tian ◽

Yang Zhang ◽

Yu Chen ◽

Min Cai ◽

Hailong Dong ◽

...

Keyword(s):

Prognostic Factor ◽

Astrocytic Glioma ◽

Negative Prognostic Factor ◽

Independent Negative Prognostic Factor

Download Full-text

Skeletal muscle loss is an independent negative prognostic factor in patients with advanced lower rectal cancer treated with neoadjuvant chemoradiotherapy

PLoS ONE ◽

10.1371/journal.pone.0195406 ◽

2018 ◽

Vol 13 (4) ◽

pp. e0195406 ◽

Cited By ~ 19

Author(s):

Yasuhiro Takeda ◽

Takashi Akiyoshi ◽

Kiyoshi Matsueda ◽

Hironori Fukuoka ◽

Atsushi Ogura ◽

...

Keyword(s):

Skeletal Muscle ◽

Rectal Cancer ◽

Prognostic Factor ◽

Neoadjuvant Chemoradiotherapy ◽

Lower Rectal Cancer ◽

Muscle Loss ◽

Negative Prognostic Factor ◽

Skeletal Muscle Loss ◽

Independent Negative Prognostic Factor

Download Full-text

Nuclear Expression of Snail Is an Independent Negative Prognostic Factor in Human Breast Cancer

Disease Markers ◽

10.1155/2013/902042 ◽

2013 ◽

Vol 35 ◽

pp. 337-344 ◽

Cited By ~ 20

Author(s):

S. Muenst ◽

S. Däster ◽

E. C. Obermann ◽

R. A. Droeser ◽

W. P. Weber ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factor ◽

Human Cancer ◽

Lymph Node Status ◽

Intrinsic Subtypes ◽

Snail Expression ◽

Mesenchymal Transition ◽

Luminal B ◽

Negative Prognostic Factor ◽

Independent Negative Prognostic Factor

Background. Snail is a key regulator of epithelial-mesenchymal transition of tumor cells. Several studies have shown nuclear Snail expression to be a negative prognostic factor in human cancer, where it is generally associated with more aggressive tumor behavior and worse survival.Objectives and Methods. To further explore the role of Snail expression in breast cancer, we conducted a study on a tissue microarray, encompassing 1043 breast cancer cases.Results. A total of 265 (25.4%) breast cancers were positive for Snail. Snail expression was significantly associated with greater tumor size, higher tumor stage and grade, positive lymph node status, and hormone receptor negative status and was differently expressed in the intrinsic subtypes of breast cancer, being the highest in the basal-like subtype and the lowest in the luminal A subtype. In multivariate analysis, Snail proved to be an independent negative prognostic factor for OS. In the intrinsic subtypes, Snail expression was a negative prognostic factor for OS in the luminal B HER2−, the luminal B HER2+, and the basal-like subtype.Conclusions. This is the first study demonstrating that nuclear Snail expression is an independent negative predictor of prognosis in breast cancer, thus suggesting that it may represent a potential therapeutic target.

Download Full-text

Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy

Lung Cancer International ◽

10.1155/2012/587424 ◽

2012 ◽

Vol 2012 ◽

pp. 1-6 ◽

Cited By ~ 4

Author(s):

A. Hallqvist ◽

F. Enlund ◽

C. Andersson ◽

H. Sjögren ◽

A. Hussein ◽

...

Keyword(s):

Prognostic Factor ◽

Induction Chemotherapy ◽

Phase Ii Study ◽

Stage Iii ◽

Egfr Mutations ◽

High Dose ◽

Kras Mutations ◽

Negative Prognostic Factor ◽

Combined Radiochemotherapy ◽

Independent Negative Prognostic Factor

Background. The main attention regarding prognostic and predictive markers in NSCLC directs towards the EGFR-targeted pathway, where the most studied genetic alterations include EGFR mutations, EGFR copy number, and KRAS mutations. We wanted to explore the prognostic impact of mutated KRAS in the stage III setting treated with high-dose radiochemotherapy. Methods. Samples were obtained from patients participating in two prospective studies of locally advanced NSCLC receiving combined radiochemotherapy: the RAKET study, a randomized phase II study where patients were treated with induction chemotherapy (carboplatin/paclitaxel) followed by concurrent radiochemotherapy, and the Satellite trial, a phase II study with induction chemotherapy (cisplatin/docetaxel) followed by radiotherapy concurrent cetuximab. The samples were analysed regarding KRAS mutations, EGFR mutations, and EGFR FISH positivity. Results. Patients with mutated KRAS had a significantly inferior survival, which maintained its significance in a multivariate analysis when other possible prognostic factors were taken into account. The prevalence of KRAS mutations, EGFR mutations, and EGFR FISH positivity were 28.8%, 7.5%, and 19.7%, respectively. Conclusion. Mutated KRAS is an independent negative prognostic factor for survival in NSCLC stage III disease treated with combined radiochemotherapy. The prevalence of KRAS mutations and EGFR mutations are as expected in this Scandinavian population.

Download Full-text